Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL
Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). BNZ-1 is an immuno-modulator drug candidate. It is a multi-cytokine inhibitor of three interleukins, that includes IL-2, IL-9, and IL-15. It is the lead asset from Bioniz Therapeutics’ platform of […]